Skip to main content

Research

The Department of Pathology is deeply invested in scientific efforts to improve treatments in our field. Learn more about our department’s investigations below.

Message from the Vice Chair

"We are driven by a shared passion for discovery and a deep commitment to advancing human health through innovative research programs and collaborative partnerships among scientists and pathologists."

Peng Ji, MD, PhD
Vice Chair of Research 

Read Full Message

Areas of Research

Members of the Department of Pathology are defining the cellular and molecular basis of disease toward the development of new and improved strategies to diagnose and treat, inherited, acquired and infectious disorders. Learn more about the work being done in our labs via the descriptions below.

Affilated Research Centers and Institutes

The faculty members of Northwestern University Feinberg School of Medicine’s Department of Pathology are engaged in research within the department and throughout Northwestern Medicine and Northwestern University. Our work throughout the community, including director appointments, illustrate the importance we put on scientific collaboration.

Research Cores

Core facilities provide cost-efficient access of state-of-the-art equipment, the most current technologies and expert technical advice to individual scientists.

Learn more about our affiliated cores

Recent Publications

The Silva pattern-based classification for HPV-associated endocervical adenocarcinoma: A single institution concordance study of trainees and gynecologic pathologists.

Felicelli C, Smith SH, Griffin B, Grubs A, Strom D, Shanes E, Strickland A, Purdy J, Novo JE, Wei JJ, Blanco LZ Jr.

Pathol Res Pract. 2024 Apr 16;257:155311. doi: 10.1016/j.prp.2024.155311. Online ahead of print.

Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer.

Tosoian JJ, Zhang Y, Xiao L, Xie C, Samora NL, Niknafs YS, Chopra Z, Siddiqui J, Zheng H, Herron G, Vaishampayan N, Robinson HS, Arivoli K, Trock BJ, Ross AE, Morgan TM, Palapattu GS, Salami SS, Kunju LP, Tomlins SA, Sokoll LJ, Chan DW, Srivastava S, Feng Z, Sanda MG, Zheng Y, Wei JT, Chinnaiyan AM; EDRN-PCA3 Study Group.

JAMA Oncol. 2024 Apr 18. doi: 10.1001/jamaoncol.2024.0455. Online ahead of print.

Estimating the serological underrecognition of patients with weak or partial RHD variants.

Ramsey G, Barriteau CM.

Transfusion. 2024 Apr 18. doi: 10.1111/trf.17810. Online ahead of print.

2-Step-Scores with optional nephropathology for the prediction of adverse outcomes for brain-dead donor kidneys in Eurotransplant.

Ernst A, Regele H, Chatzikyrkou C, Dendooven A, Turkevi-Nagy S, Tieken I, Oberbauer R, Reindl-Schwaighofer R, Abramowicz D, Hellemans R, Massart A, Ljubanovic DG, Senjug P, Maksimovic B, Aßfalg V, Neretljak I, Schleicher C, Clahsen-van Groningen M, Kojc N, Ellis CL, Kurschat CE, Lukomski L, Stippel D, Ströhlein M, Scurt FG, Roelofs JJ, Kers J, Harth A, Jungck C, Eccher A, Prütz I, Hellmich M, Vasuri F, Malvi D, Arns W, Becker JU.

Nephrol Dial Transplant. 2024 Apr 17:gfae093. doi: 10.1093/ndt/gfae093. Online ahead of print.

MAPT H2 haplotype and risk of Pick's disease in the Pick's disease International Consortium: a genetic association study.

Valentino RR, Scotton WJ, Roemer SF, Lashley T, Heckman MG, Shoai M, Martinez-Carrasco A, Tamvaka N, Walton RL, Baker MC, Macpherson HL, Real R, Soto-Beasley AI, Mok K, Revesz T, Christopher EA, DeTure M, Seeley WW, Lee EB, Frosch MP, Molina-Porcel L, Gefen T, Redding-Ochoa J, Ghetti B, Robinson AC, Kobylecki C, Rowe JB, Beach TG, Teich AF, Keith JL, Bodi I, Halliday GM, Gearing M, Arzberger T, Morris CM, White CL 3rd, Mechawar N, Boluda S, MacKenzie IR, McLean C, Cykowski MD, Wang SJ, Graff C, Nagra RM, Kovacs GG, Giaccone G, Neumann M, Ang LC, Carvalho A, Morris HR, Rademakers R, Hardy JA, Dickson DW, Rohrer JD, Ross OA; Pick's disease International Consortium.

Lancet Neurol. 2024 May;23(5):487-499. doi: 10.1016/S1474-4422(24)00083-8.

Spatial comparison of molecular features associated with resistance to pembrolizumab in BCG unresponsive bladder cancer.

Meghani K, Frydenlund N, Yu Y, Choy B, Meeks JJ.

J Immunother Cancer. 2024 Apr 16;12(4):e008571. doi: 10.1136/jitc-2023-008571.

Bhlhe40 Promotes CD4+ T Helper 1 Cell and Suppresses T Follicular Helper Cell Differentiation during Viral Infection.

Nguyen C, Kudek M, Zander R, Niu H, Shen J, Bauer A, Alson D, Khatun A, Chen Y, Sun J, Drobyski W, Edelson BT, Cui W.

J Immunol. 2024 Apr 15:ji2300355. doi: 10.4049/jimmunol.2300355. Online ahead of print.

Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation.

Roloff GW, Kosuri S, Nawas MT, DuVall AS, Patel AA, Riedell PA, Odenike O, Stock W, Larson RA, Bishop MR, Nunley E, Godley LA, Hathaway F, Del Gaudio D, Das S, Canham LE, Drazer MW.

Haematologica. 2024 Apr 11. doi: 10.3324/haematol.2023.284584. Online ahead of print.

Alzheimer's Amyloid Hypothesis and Antibody Therapy: Melting Glaciers?

Høilund-Carlsen PF, Alavi A, Castellani RJ, Neve RL, Perry G, Revheim ME, Barrio JR.

Int J Mol Sci. 2024 Mar 31;25(7):3892. doi: 10.3390/ijms25073892.

Prohibitin Expression in Antigen-Presenting Cells: Implications for Inciting Trigger in CNS IgG4-Related Disease.

Najem H, Arrieta VA, Duffy J, Tripathi S, Zannikou M, Dhiantravan S, Miska J, McCortney K, Steffens A, Walshon J, Lee Chang C, Dahdaleh NS, Sonabend AM, Smith Z, Horbinski CM, Chandler J, Heimberger AB, Balyasnikova IV.

Ann Case Rep. 2024;9(1):1607. doi: 10.29011/2574-7754.101607. Epub 2024 Jan 25.

Be a part of our future discoveries.Giving

Follow Pathology on FacebookInstagram